GlobeNewswire

ProMIS Neurosciences Announces Fiscal Year 2020 Results

Share

TORONTO and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2020.

“Despite the many challenges resulting from the COVID-19 pandemic and over the course of the past year, the value of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities across multiple neurodegenerative diseases,” stated Eugene Williams, ProMIS’ Executive Chairman.

Corporate Highlights

During 2020, we received proceeds from the exercise of warrants in the amount of $2,197,245.   In March 2021, the Company completed a US$7.0 million (CDN$8.75 million) private placement of debentures. The debentures are convertible into common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually.

In May 2020, ProMIS announced it had identified novel antagonists against the receptor for activated protein kinase C1 (RACK1) that prevent the formation of dysfunctional protein aggregates and act to restore normal function. Evidence indicates that targeting RACK1 is a promising new strategy to address the complex mechanisms involved in the pathogenesis of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).

In July 2020, the Company entered into two joint venture business arrangements (JV) with BC Neuroimmunology Lab, Inc. (BCNI). The first JV (JV1) will develop and market highly accurate, objective tests for the detection, diagnosis and monitoring of Alzheimer’s disease (AD). JV1 will offer existing blood-based assays for NfL (neurofilament light chain) and P-tau181 (phosphorylated tau181). Further assays will be developed, potentially incorporating our proprietary peptide antigens and tests for additional neurodegenerative diseases. The second JV (JV2) is a collaboration to develop a high-throughput, highly specific serological assay to accurately detect the presence of antibodies against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The Company and BCNI each own 50% of JV1 and JV2.

In July 2020, the Company announced the voting results of the Corporation's annual meeting of shareholders held in Vancouver, BC. All of the resolutions announced in the Management Proxy Circular and placed before the Meeting were approved by the shareholders. All Directors were elected, with each nominee receiving more than 75% of the votes cast.

In September 2020, ProMIS announced initiation of a program to construct and test a multivalent peptide vaccine for AD. The critical first steps in vaccine development will be carried out at the University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), a global leader in vaccine research and development.

In November 2020, the Company closed on a special warrant financing. The Company issued 16,219,581 special warrant certificates for gross proceeds of $1,946,350 ($1,636,590 net of issuance costs). Each special warrant will be exercisable, without payment of any additional consideration by the holder, into one common share and one transferrable common share purchase warrant (Warrant).

In March 2021, the special warrant financing converted into 16,219,581 common shares and 16,219,581 warrants. Each warrant entitles the holder to acquire one common share at an exercise price at $0.20 per warrant share for 60 months until November 2025.

People

In October 2020, Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, was appointed to the Company’s Scientific Advisory Board.

Financial Results

Annual Results of Operations

The Company’s net loss for the year ended December 31, 2020 was $5,662,392 compared to a net loss of $7,396,259 year ended December 31, 2019. Included in the net loss amount for the year ended December 31, 2020 were non-cash expenses of $430,242 representing share-based compensation, warrant modification and valuation and amortization of an intangible asset, compared to $655,954 for the year ended December 31, 2019. The decrease in the net loss for the year ended December 31, 2020 reflects decreased costs associated with external contract research organizations for internal programs, patent costs, share-based compensation, consultant salaries and associated costs and general corporate expenditures.

Research and development expenses for the year ended December 31, 2020 were $3,183,149, as compared to $4,735,317 in the year ended December 31, 2019. The decrease in research and development expense for the year ended December 31, 2020, compared to the same period ended December 31, 2019 reflects the conservation of existing cash resources and decreased spending on external contract research organizations for internal programs, reduced patent expense, share-based compensation, contracted research salaries and associated costs and external consulting expense.   

General and administrative expenses for the year ended December 31, 2020 were $2,481,030, as compared to $2,662,144 in the year ended December 31, 2019. The decrease for the years ended December 31,2020, compared to the same period in 2019, is primarily attributable to a reduction in consulting and professional fees and a decrease in foreign exchange losses offset by warrant modification and valuation expense.

Outlook

Following on from the completion of a US$7M (CDN$8.75M) financing in March 2021, we plan to advance progress toward our priority programs:

  • Advance the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
  • Enhance our partnering prospects by allowing us to invest in additional validation data for key R&D programs;
  • Expand our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform;
  • Advance our diagnostic programs in partnership with BCNI;
  • Achieve NASDAQ listing;
  • Expand our Board of Directors and our management team, to support a growing and ambitious scope of activity.

About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Company documents relating to the fiscal year 2020 annual report can be viewed on the System for Electronic Document Analysis and Retrieval (SEDAR) at the link below:
https://www.sedar.com/search/search_en.htm

Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)12.4.2021 15:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 12 April 2021 at 4:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the number of Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 9 April 2021 below five (5) per cent Sampo plc's total stock. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B) Resulting situation on the date on which thres

Vertex Welcomes Dynamic Leader Yvette C. Burton, Ph.D. As Chief People Innovation Officer12.4.2021 14:47:00 CEST | Press release

Executive Leadership to Advance Company’s Global Workforce Strategy KING OF PRUSSIA, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, is honored to welcome Yvette C. Burton, Ph.D. as its first Chief People Innovation Officer, effective immediately. Dr. Burton is responsible for shaping the company’s global strategic workforce planning efforts and leading organizational programs to advance inclusion and diversity. Burton comes to Vertex from Columbia University, where she was the academic director of the school’s Human Capital Management Program. She will draw on her executive expertise, including over 20 years in high-impact human capital strategies for the media, consumer, industrial product, and defense industries, to lead and engage employees worldwide. Burton was also named to Crain's New York inaugural list of Notable LGBTQ Leaders and Executives in 2020. “We welcome Yvette and her rare c

Industry Leading SAFR Facial Recognition for Live Video Integrated with Geutebrück VMS12.4.2021 13:00:00 CEST | Press release

Featuring real-time, automated, low-bias identification of opt-in staff and persons of interest SEATTLE, April 12, 2021 (GLOBE NEWSWIRE) -- SAFR from RealNetworks, Inc. (NASDAQ: RNWK) today announced that its SAFR facial recognition system for live video is now integrated with the Geutebrück G-Core VMS (Video Management System). SAFR for Geutebrück is an AI layer that runs on top of the G-Core VMS which provides advanced video analytics that save time and increase efficiency of surveillance operations. The best-in-class integration features live video overlays that display event details, streamlined enrollment of individuals appearing on the Geutebrück VMS directly into the SAFR identity database, and custom alarms and notifications that notify security personnel of SAFR events directly within the VMS. With so many cameras deployed, it’s impossible for security staff to monitor them effectively. SAFR matches faces appearing in live video feeds against watchlist images more effectively

Rockridge Stakes Additional Ground at the Knife Lake Copper Project, Saskatchewan12.4.2021 13:00:00 CEST | Press release

VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd. (TSX-V: ROCK) (OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge” or the “Company”) is pleased to announce that it has recently acquired additional mineral rights through staking at its Knife Lake Copper Project located in Saskatchewan, Canada (the “Knife Lake Project” or “Property”). The Knife Lake Project, now consisting of 81 dispositions totaling 55,471 hectares (137,069 acres), is an advanced-stage copper, silver, zinc and cobalt exploration property in Saskatchewan. With the recent staking, the Company has increased the project area by 70% from 32,663 hectares (80,712 acres). Knife Lake Claims Map: https://www.rockridgeresourcesltd.com/_resources/images/Knife-Lake-Region-20210331-003.jpg Based on encouraging observations made during the current drill program the newly acquired claims are considered to be highly prospective for VMS mineralization. The staking completed has added to the land package s

Signify share repurchase periodic update12.4.2021 13:00:00 CEST | Press release

Press Release April 12, 2021 Signify share repurchase periodic update Eindhoven, the Netherlands –Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 131,684 shares in the period April 6 to April 9, 2021. The shares were repurchased at an average price of EUR 44.36 per share and an aggregate amount of EUR 5.8 million. These repurchases were made as part of the company’s repurchase program, which was announced on February 25, 2021. Signify will use the shares to cover obligations arising from its long-term incentive performance share plan and other employee share plans. The total number of shares repurchased under this program to date is 968,157 shares for a total consideration of EUR 39.3 million. Details on the share buyback transactions can be found here. --- END --- For further information, please contact: Signify Investor Relations Thelke Gerdes Tel: +31 6 1801 7131 E-mail: thelke.gerdes@signify.com Signify Corporate Communications Elco

Effnet licenses its ASN.1 5G Toolset and 5G gNB CU-UP software components12.4.2021 12:07:15 CEST | Press release

Luleå, 2021-04-12 -- Effnet, a subsidiary of Effnetplattformen AB and a leading provider of 5G protocol stack software for terminals and containerized 5G RAN software as well as Header Compression software, announces today that it has licensed its ASN.1 5G Toolset and 5G gNB CU-UP software components to a leading provider of open and cloud-native 4G and 5G RAN software solutions. Effnet ASN.1 5G Toolset uses modern C++. It is portable, robust and provides high performance. It currently has support for ASN.1 in 3GPP Release 15 (RRC, F1AP, E1AP, NGAP, XnAP and NRPPa) specifications and the O-RAN E2AP specification. For more information, visit http://www.effnet.com/products/asn1/. Effnet 5G gNB CU-UP is a high quality and high-performance user plane software solution used in the Central Unit (CU) of a 5G gNB. Together with the Effnet DU software, this is a critical component to deliver data traffic (user plane) at exceedingly high rates. The software can deliver better radio resource effi

Statkraft bygger tre vindparker i Chile – verdens sørligste land12.4.2021 12:00:00 CEST | Pressemelding

(Santiago/Oslo, 12. april 2021) Statkraft skal for første gang bygge vindkraftverk i Chile, og øker dermed sin produksjonskapasitet for fornybar energi i det søramerikanske landet, hvor etterspørselen etter vann-, vind- og solkraft er stigende. Sammen med selskapets eksisterende vannkraftportefølje i Chile, vil Statkraft nå en produksjonskapasitet på 366 megawatt (MW) innen utgangen av 2023. Det 102 MW store vindprosjektet Torsa består av tre vindparker, med til sammen 19 turbiner fra den tyske produsenten Nordex. Samlet forventes vindparkene å produsere mer enn 300 GWh med fornybar energi i året – nok til å forsyne 100.000 gjennomsnittlige chilenske hjem. Prosjektet ligger i O’Higgins-regionen, 124 kilometer sør for hovedstaden Santiago. - Disse tre vindparkene øker ikke bare vår produksjonskapasitet i Chile; de utvider vår fornybarportefølje til å for første gang omfatte vindkraft. Framover planlegger vi også å inkludere solkraft i produksjonsmiksen vår, sier Statkrafts konserndirekt